MEG3 has been demonstrated to upregulate miR-133a-3p and inhibit osteogenic differentiation in bone marrow MSCs from patients with postmenopausal osteoporosis, which also plays an essential role in osteogenic differentiation in bone marrow MSCs, partially by activating BMP4 transcription [39, 40]. This evidence concerns the gene MEG3 and postmenopausal osteoporosis.